Preclinical research across multiple cancer types now shows that the NAD+ salvage pathway, the same biological mechanism targeted by popular anti-aging supplements like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), can directly fuel tumor growth. The findings create a sharp tension for the millions of consumers taking these supplements to slow aging: the very pathway they are boosting may, in certain contexts, accelerate cancer cell proliferation. While some studies also point to immune benefits from NAD+ supplementation, the emerging picture is far more complicated than supplement marketing suggests.
How NAD+ Fuels Fast-Dividing Cancer Cells
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme that every cell needs for energy metabolism and DNA repair. Levels decline with age, which is why NMN and NR have become bestselling supplements marketed as ways to restore youthful cellular function. NR is a salvageable NAD+ precursor that converts to NAD+ through a two-step or three-step pathway. But cancer cells also depend heavily on NAD+. A review published in Trends in Cancer found that continuous replenishment of NAD promotes the proliferation and survival of fast-dividing cancer cells because elevated NAD levels sustain the metabolic demands of rapid division. That biological reality sets up a conflict at the heart of the anti-aging supplement industry: what aging cells need to recover, cancer cells also need to thrive.
Colorectal Cancer Models Show Direct Tumor Rescue
The most striking evidence comes from colorectal cancer research. In APC mutation-driven colorectal cancer models, the enzyme nicotinamide phosphoribosyltransferase (NAMPT), which is the rate-limiting step in the NAD salvage pathway, was directly tied to tumor proliferation through Wnt/beta-catenin signaling. When researchers inhibited NAMPT, tumor growth slowed. But when they added NMN to reverse the NAMPT inhibition, tumors resumed growing. In practical terms, the supplement’s active product was enough to override a targeted anti-cancer intervention and restore the tumor’s energy supply.
This is not a minor mechanistic detail. It suggests that exogenous NAD+ precursors can directly counteract therapeutic strategies designed to starve tumors of metabolic fuel. For anyone with undiagnosed colorectal polyps or early-stage mutations, the implication is uncomfortable: supplementing with NMN could, in theory, feed a tumor they do not yet know they have. Although these data come from animal and cell models rather than people, they highlight a plausible risk pathway that has not been meaningfully addressed in consumer-facing marketing or labeling.
Pancreatic and Skin Cancer Add to the Concern
The colorectal findings do not stand alone. In pancreatic ductal adenocarcinoma, NAMPT expression is elevated in both tumor tissues and cancer cell lines. Pharmacologic inhibition of NAMPT impaired tumor growth and enhanced chemotherapy activity in mouse models of pancreatic cancer. The logic runs in the same direction as the colorectal data: when cancers depend on NAD salvage for survival, cutting off that supply line slows them down. Flooding the system with NAD+ precursors would work against that strategy by replenishing the very metabolite the tumor is being deprived of.
Separately, a study testing oral NMN in an ultraviolet radiation-driven skin cancer model in mice found that while NMN successfully increased tissue NAD+ content, it did not reduce any tumor development endpoint, including onset, number, size, or growth rate. Polypodium leucotomos, another supplement tested in the same study, also failed to protect against UVR-induced skin cancer. The skin cancer results are less alarming than the colorectal rescue data, but they reinforce a consistent pattern: raising NAD+ levels does not appear to protect against cancer and, depending on the tumor type, may actively support it.
The Immune System Complication
The story is not entirely one-sided, which is precisely what makes it so difficult for consumers to interpret. Research published in Cell Reports found that boosting NAD+ can enhance anti-tumor immunity in mouse models using both CAR-T cell therapy and anti-PD-1 checkpoint inhibitors. The mechanism involves restoring the metabolic fitness of tumor-infiltrating T cells, which often become exhausted in the tumor microenvironment. With more NAD+ available, these immune cells regained their ability to kill cancer cells more effectively, improving responses to immunotherapy in preclinical settings.
Additional preclinical work in triple-negative breast cancer models showed that NAD+ supplementation suppressed metastasis through the SIRT1-p66Shc signaling axis. In that context, NAD+ did not simply energize rapidly dividing tumor cells; it altered signaling pathways in a way that constrained the cancer’s ability to spread. So in at least some cancer types, NAD+ appears to help the body fight tumors rather than feed them. The divergence likely depends on whether the dominant effect in a given cancer setting is direct tumor metabolism or immune and stromal cell function, a distinction that current supplement labels do not and cannot make.
Human Trials Confirm Bioavailability, Not Safety in Cancer
One thing the research has established clearly is that these supplements work as advertised in one narrow sense: they raise NAD+ levels in humans. Controlled trials in healthy volunteers and people with metabolic risk factors have repeatedly shown that oral NR and NMN increase circulating and tissue NAD+ and are generally well tolerated over weeks to months. A recent randomized trial in older adults, for example, demonstrated that daily NMN substantially elevated whole-blood NAD+ without major short-term safety signals, confirming that the compound is both orally bioavailable and biologically active.
What these studies have not done is rigorously evaluate cancer risk. Most human trials have been small, short, and focused on endpoints such as insulin sensitivity, blood lipids, or fatigue rather than tumor incidence. Participants with active cancer are typically excluded, and follow-up is rarely long enough to detect differences in cancer outcomes. A recent mechanistic study in humans and mice used NMN as a tool to probe the metabolic effects of NAD+ repletion and reported improved muscle energetics and cardiometabolic markers, but it was not designed to assess malignancy risk or progression.
Newer work underscores how context-dependent the biology may be. A 2024 investigation in NAD+ metabolism and clonal hematopoiesis suggested that age-related blood cell clones with oncogenic mutations can interact with metabolic pathways in unexpected ways, potentially altering how systemic interventions influence cancer risk over time. While this study did not test NMN or NR supplements directly, it reinforces the idea that manipulating core metabolic cofactors in older adults (precisely the population most likely to use anti-aging products) could have complex, long-latency effects that short trials will miss.
Regulators have not yet required long-term cancer surveillance for NAD+ precursors, in part because they are marketed as dietary supplements rather than drugs in many jurisdictions. That leaves clinicians and consumers relying on mechanistic reasoning and preclinical models to infer risk. The U.S. National Library of Medicine’s biomedical databases now contain dozens of animal and cell studies probing NAD+ in oncology, but almost no large-scale epidemiologic data on real-world supplement users.
What This Means for Consumers Now
For people with a history of cancer, known precancerous lesions, or strong familial risk, the current evidence base argues for caution. Tumor types such as colorectal and pancreatic cancers have shown clear dependence on the NAD salvage pathway in preclinical models, and direct “rescue” of tumors by NMN has been documented in mice. Until human data clarify whether similar effects occur in patients, taking high-dose NAD+ precursors in this group could be unwise without explicit guidance from an oncologist.
For generally healthy older adults, the risk-benefit calculus is murkier. Short-term trials suggest that NR and NMN can improve some metabolic markers and may modestly enhance physical performance, but none has demonstrated a hard clinical benefit such as reduced cardiovascular events, disability, or mortality. Against that uncertain upside, there is a theoretical but biologically plausible downside: inadvertently supporting the growth of an early, undiagnosed cancer or altering clonal dynamics in aging tissues in ways that only become evident years later.
Experts emphasize that the right research response is not panic but rigor. Long-term randomized trials with cancer surveillance, careful stratification by baseline risk, and integration of tumor genomic data will be needed to map where on the spectrum, from harmful to helpful,NAD+ supplementation falls for specific populations and cancer types. In the meantime, consumers who choose to use NMN or NR should do so with a realistic understanding: these are potent metabolic modulators, not benign vitamins, and the same biochemical pathways that promise slower aging may, under the wrong circumstances, give cancer cells a crucial edge.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
